Categories
Change Password!
Reset Password!
Sacubitril/valsartan therapy remarkably lowers the incidence of cardiac arrhythmias and the need for device-based interventions in patients with HFrEF.
A recent study offers promising evidence that sacubitril/valsartan (SV) may markedly reduce life-threatening arrhythmias and the need for defibrillator interventions in patients with heart failure with reduced ejection fraction (HFrEF) who have implantable cardiac devices.
The study, conducted at a specialized heart failure outpatient clinic, encompassed 181 patients diagnosed with HFrEF who were treated with SV and followed for a minimum of 12 months. The average age of volunteers was 63.39 years (±12), with 36.5% of the group being male. Notably, 60.8% of the patients had an implantable cardioverter-defibrillator (ICD), and others had cardiac resynchronization therapy defibrillators (CRT-D).
Researchers focused on arrhythmic events and device responses, including the incidence of ventricular tachycardia, ventricular fibrillation, non-sustained ventricular tachycardia, supraventricular tachycardia, and the need for anti-tachycardia pacing or defibrillation shocks. Device interrogations before and after SV therapy revealed substantial improvements:
These results suggest that SV may provide antiarrhythmic benefits beyond its established role in reducing mortality and hospitalization in heart failure patients. By lowering the burden of dangerous electrical disturbances and diminishing reliance on device therapy, SV could contribute to improved quality of life and long-term outcomes for this high-risk population. While SV is a cornerstone in HfrEF care, this study adds to the growing body of evidence supporting its role in arrhythmia prevention—particularly in those already equipped with ICD or CRT-D devices.
Annals of Noninvasive Electrocardiology
The Effect of Sacubitril/Valsartan on Supraventricular and Ventricular Arrhythmias in Patients With Heart Failure
Alireza Arzhangzadeh et al.
Comments (0)